Last Updated : August 18, 2014
Details
FilesGeneric Name:
Pomalidomide
Project Status:
Complete
Therapeutic Area:
Multiple Myeloma
Manufacturer:
Celgene Inc.
Brand Name:
Pomalyst
Project Line:
Reimbursement Review
Project Number:
PC0036-000
Strength:
1, 2, 3, 4 mg capsules
Tumour Type:
Myeloma
Indications:
Multiple Myeloma
Funding Request:
In combination with low-dose dexamethasone for patients with multiple myeloma for whom both bortezomib and lenalidomide have failed and who have received at least two prior treatment regimens and have demonstrated disease progression on the last regimen
Review Status:
Complete
Pre Noc Submission:
Yes
Sponsor:
Celgene Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:
Files
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Last Updated : August 18, 2014